vorinostat has been researched along with Nervous System Disorders in 4 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "This multi-institutional phase II trial assessed the activity and toxicity of a new histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamic acid--SAHA) in patients with recurrent or persistent epithelial ovarian or primary peritoneal carcinoma." | 9.13 | A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. ( Bender, DP; Hoffman, JS; Modesitt, SC; Sill, M, 2008) |
| "This multi-institutional phase II trial assessed the activity and toxicity of a new histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamic acid--SAHA) in patients with recurrent or persistent epithelial ovarian or primary peritoneal carcinoma." | 5.13 | A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. ( Bender, DP; Hoffman, JS; Modesitt, SC; Sill, M, 2008) |
| "Mainly sight saw in cancer chemotherapeutics, HDAC inhibitors have also found a promising role in other diseases (neurodegenerative disorders, cardiovascular diseases, and viral infections) and successfully entered in various combination therapies (pre-clinical/clinical stages)." | 2.72 | Paradigm shift of "classical" HDAC inhibitors to "hybrid" HDAC inhibitors in therapeutic interventions. ( Chatterjee, DR; Contractor, D; Jain, A; Kumar, D; Nagpure, M; Rana, P; Satpute, DP; Vaidya, GN; Venkatesh, A, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vaidya, GN | 1 |
| Rana, P | 1 |
| Venkatesh, A | 1 |
| Chatterjee, DR | 1 |
| Contractor, D | 1 |
| Satpute, DP | 1 |
| Nagpure, M | 1 |
| Jain, A | 1 |
| Kumar, D | 1 |
| Potera, C | 1 |
| Rouaux, C | 1 |
| Loeffler, JP | 1 |
| Boutillier, AL | 1 |
| Modesitt, SC | 1 |
| Sill, M | 1 |
| Hoffman, JS | 1 |
| Bender, DP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I/II Study of Romidepsin in Combination With Abraxane in Patients With Metastatic Inflammatory Breast Cancer[NCT01938833] | Phase 1/Phase 2 | 9 participants (Actual) | Interventional | 2014-04-30 | Terminated (stopped due to Closed by Sponsor) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for vorinostat and Nervous System Disorders
| Article | Year |
|---|---|
Paradigm shift of "classical" HDAC inhibitors to "hybrid" HDAC inhibitors in therapeutic interventions.
Topics: Animals; Cardiovascular Diseases; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Humans; Molec | 2021 |
Targeting CREB-binding protein (CBP) loss of function as a therapeutic strategy in neurological disorders.
Topics: Animals; Apoptosis; CREB-Binding Protein; Drug Delivery Systems; Enzyme Inhibitors; Histone Deacetyl | 2004 |
1 trial available for vorinostat and Nervous System Disorders
| Article | Year |
|---|---|
A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma; Disease-Free Survival; Female; Gas | 2008 |
1 other study available for vorinostat and Nervous System Disorders
| Article | Year |
|---|---|
Silent advances.
Topics: Antineoplastic Agents; Gene Expression Regulation; Gene Silencing; Histone Deacetylases; Humans; Hyd | 2004 |